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Results Among the 240 patients included in the study, 
136 had received mFOLFOX6 therapy and 104 had 
received XELOX therapy. Although the frequency of HSRs 
did not differ between the two groups, incidence of HSRs 
in the first cycle was higher in the XELOX therapy group. 
Treatment method or cumulative dosage was not iden-
tified as a risk factor for HSR; however, the incidence of 
≥grade-2 HSR was higher in cases where the cumulative 
L-OHP dosage was ≥600 mg/m2 and in patients in whom 
dexamethasone was not co-infused with L-OHP.
Conclusion Although HSR rates were comparable 
among patients treated with mFOLFOX6 and XELOX, 
HSRs tended to occur more frequently during the first 
cycle of XELOX therapy as compared to that with mFOL-
FOX6 therapy. Our findings warrant careful assessment of 
≥grade-2 HSRs in patients who are prescribed cumulative 
L-OHP dosages of ≥600 mg/m2.
Keywords Oxaliplatin · Hypersensitivity reactions · 
XELOX therapy · FOLFOX therapy · Colorectal cancer
Introduction
In a previous trial on patients with advanced colorectal 
cancer [1], FOLFOX4 therapy [5-fluorouracil (5-FU), levo-
folinate calcium (LV) and oxaliplatin (L-OHP) infusions] 
was shown to be superior to conventional therapy (5-FU 
and LV infusions) in terms of progression-free survival and 
response rates. Based on these results, L-OHP is positioned 
as a key drug in the treatment of colorectal cancer. Further, 
modified FOLFOX6 (mFOLFOX6) and capecitabine plus 
L-OHP (XELOX) therapies are frequently used for these 
patients [2, 3].
Abstract 
Purpose Although hypersensitivity reactions (HSRs) 
to oxaliplatin (L-OHP) therapy are well-documented, few 
reports have compared different therapies in terms of HSR 
occurrence. In this study, we compared the frequency and 
pattern of HSRs to modified FOLFOX6 (mFOLFOX6; 
5-fluorouracil, levofolinate calcium and L-OHP infusions) 
and XELOX (capecitabine and L-OHP) therapies, and 
sought to identify risk factors associated with HSRs.
Methods Patients who had received mFOLFOX6 or 
XELOX chemotherapeutic regimens for unresectable colon 
or rectal cancer or as adjuvant chemotherapy following 
colon cancer surgery between April 2012 and August 2015 
were included. Potential correlation between treatment 
modalities (regimen, dosage and route of administration of 
L-OHP, and injection timing for dexamethasone adminis-
tration) and HSRs was assessed.
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Platinum-based compounds are in use as anticancer 
agents since the 1970s, and have been developed in the fol-
lowing order: cisplatin, carboplatin, and L-OHP. Despite 
their efficacy as anticancer agents, these drugs produce 
serious side effects and hypersensitivity reactions (HSRs). 
Although the type of HSR, incidence rate and time to 
occurrence tend to vary among platinum compounds [4], 
the ensuing details remain largely unknown. Reported rates 
of HSRs to L-OHP, in the absence of any countermeasures, 
range from 8.9 to 23.8% [5–17]. In a comparative study of 
three platinum-based compounds published in 2010, HSRs 
to L-OHP typically occurred after six treatment cycles [4]. 
Similarly, in a study of eight regimens, including FOLFOX 
and XELOX, the mean and median (range) numbers of 
treatment cycles for HSRs were 7.9 and 8 (4–12), respec-
tively[15]. In contrast, in a study of more than six regimens, 
including FOLFOX4 and GEMOX (L-OHP+ gemcitabine) 
therapies, HSRs were reported at a median of 4.7 cycles 
[16]. However, because differing treatment regimens likely 
have differing HSR onset times, analyses of HSRs under 
conditions of mixed treatment methods are likely biassed.
Known risk factors for HSRs to L-OHP include female 
sex [16, 18], young age [16, 18], initial treatment with a 
platinum-based anticancer agent [16, 18] and repeated 
administration of L-OHP [11]. In a study of XELOX 
therapy by Yoshida et  al. [19], the combination of dexa-
methasone (Dex; 6.6 mg) and L-OHP (a total of 13.2 mg 
Dex) reduced the incidence of HSRs to 4.1%; further, only 
grade-1 skin symptoms were observed with co-administra-
tion of Dex and L-OHP. This suggests that the amount or 
timing of steroid administration has a strong effect on HSR 
occurrence.
Here we report a retrospective comparison between the 
frequency and pattern of HSRs in patients treated with 




Subjects included patients who received mFOLFOX6 or 
XELOX therapy as cancer chemotherapy for unresectable 
colon or rectal cancer, or as adjuvant chemotherapy follow-
ing colon cancer surgery, at the Fujita Health University 
Hospital between April 2012 and August 2015. All patients 
who did not agree with the main purpose of the study were 
excluded. Patients who received mixed treatment with 
XELOX and mFOLFOX6 therapies, administered with pre-
treatment steroids or anti-allergic drugs or have missing 
data due to a change of hospital or death during treatment 
were excluded.
Investigations
This was a retrospective study based on patient data col-
lected from electronic patient files available in the data-
bases of Fujita Health University Hospital.
The mFOLFOX6 and XELOX regimens are illustrated 
in Fig.  1. Dosages of anticancer agents were titrated to 
patients’ condition.
Data on the following variables were extracted: age 
at the start of the study; sex; body height; body weight; 
body surface area; cancer stage and metastasis; detailed 
treatment history (past chemotherapy, history of plati-
num-based therapies, regimen used, dosage/interval/route 
of administration of L-OHP, timing and amount of Dex, 
pre-treatment with steroids/antihistamines/anti-inflamma-
tory drugs); and  allergy-related information. Regarding 
allergies, the following items were obtained: vital signs 
(body temperature, blood pressure, respiratory rate, etc.), 
whether steroids/antihistamines/anti-inflammatory drugs 
were used, drug type, administration route, the presence 
or absence of a response to treatment, whether there had 
been prophylactic treatment and the drug type, whether 
any treatment had required hospitalization for HSR, and 
whether the HSR was protracted. In addition, descrip-
tions related to the following items were used: dermal and 
mucosal symptoms (rash, eczema, pruritus, rubefaction, 
edema, and tumefaction), respiratory symptoms (dysp-
nea, respiratory stenosis, stridor, and hypoxemia), cardio-
vascular symptoms (hypotension and disturbance of con-
sciousness), persistent digestive symptoms (abdominal 
colic and vomiting), and other symptoms (chills, nasal 
discharge, articulation disorders, etc.). We also investi-
gated whether there was a relationship between persis-
tent digestive symptoms and adverse effects of anticancer 
agents. Blood biochemical parameters included serum 
levels of albumin, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), serum creatinine (Scr) 
and eGFR at the commencement of treatment. Initial (in 
the first course) and cumulative dosages of L-OHP were 
recorded. In the event of an allergic or anaphylactic epi-
sode, the cumulative dosages received till that time were 
used in the analysis. Information related to allergic pre-
disposition included history of allergy to drugs, food and 
pollen, related skin disorders (atopic and contact derma-
titis) and specific history of allergy to platinum including 
that to L-OHP, cisplatin or carboplatin.
Assessment
HSR severity was determined according to the Common 
Terminology Criteria for Adverse Events (CTCAE) v4.0.
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Statistical analysis
Normally distributed variables are expressed as 
mean ± standard deviation (SD); non-normally distributed 
variables are expressed as median [interquartile range 
(IQR)]. Parametric and non-parametric pairwise com-
parisons were performed using t test and Mann–Whitney 
U test, respectively. Ratios were compared using Chi-
squared test, and risk factors for allergy were identified 
on univariate analysis. Subsequently, factors with hazard 
rates of less than 20% were incorporated in the multivari-
ate logistic regression model. Goodness of fit was tested 
using Hosmer–Lemeshow tests. All statistical analyses 
were performed using SPSS software Ver. 22.0 (IBM 
Corporation, Armonk, NY, USA). Differences and asso-
ciations with P values <0.05 were considered statistically 
significant.
Ethics
The study protocol was approved by the Epidemiology and 




A total of 335 patients were enrolled in the study. Among 
these, 25 had received mixed treatment with XELOX 
and mFOLFOX6 therapies; in 13 patients, pre-treatment 
steroids or anti-allergic drugs were administered; data 
pertaining to 57 patients were missing ostensibly due to 
change of hospital or death during treatment. The remain-
ing 240 patients included 136 patients in the mFOLFOX6 
therapy group and 104 in the XELOX therapy group. No 
significant differences in demographic parameters were 
identified between the study groups at the start of the 
treatment (Table 1). However, differences were observed 
with respect to the dosage and route of administration of 
L-OHP and Dex and that of panitumumab administra-
tion (Table  1). At the start of the treatment, patients in 
the mFOLFOX therapy group had lower albumin levels 
and higher AST levels than those in the XELOX therapy 
group (Table 1).
Fig. 1  Chemotherapy regimens. Dex dexamethasone, L-OHP oxaliplatin, LV levofolinate, 5-FU 5-fluorouracil
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Risk factors for HSR
Potential risk factors for HSRs are presented in Table  2. 
Although treatment methods, cumulative L-OHP dosages, 
administration of monoclonal antibodies, concurrent ster-
oid and L-OHP treatments, albumin and AST levels were 
not related to HSR, a body surface area of ≥1.57 m2 was 
significantly associated with a higher risk of HSR.
Comparisons of HSRs
The incidence of HSR in the mFOLFOX and XELOX ther-
apy groups were 14.0 and 19.2%, respectively; no signifi-
cant between-group difference was observed in this respect 
(P = 0.27).
No significant between-group difference was observed 
with respect to the severity of HSR (Table 3). However, the 
number of treatment cycles, dosages and routes of L-OHP 
administration differed between the groups (Table  3). No 
significant differences in cumulative dosages (mg/m2 or 
mg) were observed.
Incidence of hypersensitivity reaction
The relationship between the number of treatment cycles 
and HSRs was compared between the treatment groups. 
Comparisons of the first cycle and the four subsequent 
cycles indicated significantly more HSR occurrences dur-
ing the first cycle of XELOX therapy than those during the 
first cycle of mFOLFOX therapy (Fig.  2). Of six patients 
Table 1  Patient characteristics
L-OHP oxaliplatin, Bmab bevacizumab, Pmab panitumumab, Dex dexamethasone, ASL aspartate aminotransferase, ALT alanine aminotrans-
ferase, Scr serum creatinine, eGFR estimate glomerular filtration rate
mFOLFOX6 therapy (n = 136) XELOX therapy (n = 104) P value
Age (years) 66.0 (58.0–72.3) 65.5 (55.8–70.0) 0.067
Sex (male, female) 56, 80 51, 53 0.23
Body surface area  (m2) 1.56 (1.42–1.69) 1.59 (1.45–1.72) 0.48
Skin disease career (%) 5.1 5.8 0.83
History of allergy to platinum (%) 27.9 28.8 0.88
History of treatment with L-OHP (%) 2.2 2.9 0.93
Medical history with L-OHP(%) 20.6 21.2 0.91
Stage (%)




Metastasis (%) 79.4 69.2 0.071
L-OHP
 By infusion port (%) 100 26.0 <0.001
 Dosage (mg/m2/cycle) 82.2 (77.2–84.5) 123.0 (109.4–127.0) <0.001
 Cumulative dosage (mg/m2) 609.1 (417.1–919.1) 651.3 (454.4–942.1) 0.55
 Cumulative dosage (mg) 915.0 (627.5–1469.5) 1000.0 (625.2–1502.9) 0.60
Monoclonal antibody
 Bmab (%) 42.6 41.3 0.92
 Pmab (%) 11.0 0 0.001
Steroid
 Dex dosage (mg/cycle) 8.06 ± 0.72 7.93 ± 0.44 0.17
 Co-administration with L-OHP (%) 0 74.0 0.001
 Pre-medication with steroid except Dex (%) 10.3 16.3 0.17
Laboratory data
 Albumin (g/dL) 3.8(3.2–4.1) 4.0 (3.7–4.3) 0.002
 AST (IU/L) 23.0 (17.8–34.0) 21.0 (17.0–28.0) 0.047
 ALT (IU/L) 19.0 (12.0–30.0) 17.5 (12.0–26.0) 0.50
 Scr (mg/dL) 0.70 (0.61–0.88) 0.71 (0.58–0.83) 0.45
 eGFR (mL/min/1.73 m2) 75.2 (63.0–89.4) 78.2 (66.2–93.1) 0.30
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who showed HSRs in the first cycle, one patient had a his-
tory of L-OHP administration, whereas the other five had 
never received L-OHP. Moreover, no differences in age, 
sex, or body surface area were identified between those 
who developed HSRs in the first cycle and those who did 
not (data not shown). In intergroup comparisons, 85% of 
HSR events in the XELOX therapy group occurred before 
cycle No. 10, whereas 52.7% occurred at or after cycle 
No. 10 in the mFOLFOX therapy group, showing a differ-
ence in the timing of HSR occurrence (P = 0.031). Finally, 
Table 2  Risk factors for hypersensitivity reaction
Risk factors are analysed with multivariable logistic regression models
L-OHP oxaliplatin, Bmab bevacizumab, Pmab panitumumab, Dex dexamethasone, AST aspartate aminotransferase, ALT alanine aminotrans-
ferase, Scr creatinine, eGFR estimated glomerular filtration rate
Hosmer–Lemeshow test, P = 0.62
Univariate analysis Multivariate analysis
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Age (years) 1.03 (0.99–1.06) 0.13 1.03 (0.99–1.06) 0.15
Female 0.65 (0.32–1.32) 0.24
Body surface area ≥1.57 m2 1.79 (0.89–3.60) 0.11 2.18 (1.02–4.65) 0.045
Skin disease career 0.41 (0.052–3.28) 0.40
Allergic history 0.72 (0.32–1.61) 0.43
Platinum allergic history 5.50 (1.07–28.33) 0.042 4.97 (0.82–30.06) 0.081
Medical history with L-OHP 1.91 (0.89–4.10) 0.10 1.58 (0.64–3.94) 0.33
Metastasis 2.02 (0.80–5.09) 0.14 1.38 (0.50–3.79) 0.54
mFOLFOX6 therapy 0.68 (0.34–1.36) 0.28
L-OHP dosage (mg/m2/cycle) 1.00 (0.99–1.02) 0.60
L-OHP cumulative dosage (mg/m2) 1.00 (1.00–1.00) 0.29
L-OHP cumulative dosage (mg) 1.00 (1.00–1.00) 0.16 1.00 (1.00–1.00) 0.61
Bmab 1.77 (0.89–3.52) 0.11 1.64 (0.77–3.49) 0.20
Pmab 1.31 (0.35–4.89) 0.69
Steroid administered with L-OHP at the same time 0.80 (0.38–1.71) 0.57
Dex dosage (mg/cycle) 1.00 (0.55–1.81) 1.00
Pre-medication with steroid except Dex 1.28 (0.49–3.36) 0.62
Albumin (g/dL) 0.77 (0.46–1.28) 0.30
AST (IU/L) 1.00 (1.00–1.01) 0.12 1.00 (1.00–1.01) 0.59
ALT (IU/L) 1.01 (1.00–1.01) 0.14 1.00 (1.00–1.01) 0.42
Scr (mg/dL) 1.13 (0.23–5.61) 0.89
eGFR (mL/min/1.73 m2) 1.00 (0.98–1.01) 0.62
Table 3  Patients with 
hypersensitivity reactions
HSR hypersensitivity reaction, L-OHP oxaliplatin, Dex dexamethasone
mFOLFOX6 therapy (n = 19) XELOX therapy (n = 20) P value






 By infusion port (%) 100 45.0 <0.001
 Dosage (mg/m2/cycle) 82.2 (77.2–84.5) 123.0 (109.4–127.0) <0.001
 Cumulative dosage (mg/m2) 628.6 (471.4–1018.9) 599.5 (127.5–873.5) 0.32
 Cumulative dosage (mg) 956.0 (720.0–1670.0) 990.0 (222.5–1570.0) 0.55
 Number of cycles 10.0 (6.0–14.5) 5.5 (1.0–9.0) 0.018
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kinetic analyses of cumulative dosages (mg/m2 or mg) 
revealed no significant differences between the two groups 
(data not shown).
Severity of HSR
Incidence rates of grade-1, grade-2 and higher grade HSRs 
were compared between those who received Dex co-infu-
sions with L-OHP and those who did not. Incidence rates 
of grade-2 and higher grade HSRs were lower in patients 
who received Dex co-infusion (36.4%) as compared to that 
in patients who did not (85.7%; P = 0.0072).
The median cumulative dosage of L-OHP administered 
to patients who experienced HSRs was 628.6 (mg/m2). 
Thus, we divided these patients into two subgroups accord-
ing to whether or not the cumulative dosage of L-OHP was 
less or more than 600 mg/m2 and compared incidence rates 
of grade-1, grade-2 and higher grade HSR. The incidence 
of ≥grade-2 HSRs was significantly (P = 0.025) less among 
those treated with <600-mg/m2 L-OHP (52.6%) than in 
those treated with ≥600-mg/m2 L-OHP (90.0%).
Discussion
The present analyses showed no differences in HSR inci-
dence between patients who received mFOLFOX6 (14.0%) 
and XELOX (19.2%) therapies, although HSR incidence 
rates in the present study were somewhat lower than those 
in previous reports of FOLFOX therapy (17.0–23.8%) 
[7–10, 13]. In a smaller study [14], HSR incidence rates 
were 16.7 and 15.0% in subjects who received XELOX 
and XELOX+ bevacizumab therapies, respectively. These 
rates were slightly lower than those observed in the pre-
sent XELOX-treated cohort. However, the reported L-OHP 
HSR rates have tended to range widely from 8.9 to 23.8% 
in previous studies [5–17], which included patients with 
different treatment backgrounds. Therefore, we assume that 
the present HSR rates are within the expected range.
In previous analyses of potential risk factors for HSR 
occurrence, female sex, young age, and initial treatment 
with platinum-based anticancer agents were identified as 
risk factors by Parel et al. [16] and repeated L-OHP admin-
istration was identified as risk factors by Shao et al. [11]; 
however, these risk factors did not show any appreciable 
effects in the present study. This discrepancy may reflect 
differences in study conditions, including study periods 
(2004–2011 and 2006–2007, respectively), and different 
anticancer and adjuvant therapies for different cancer types. 
In addition, racial difference between the study populations 
may have affected the results. Sugihara et  al. [20] com-
pared rates of adverse events due to FOLFOX4 therapy 
in two Asian studies and four Western studies and found 
no racial differences in HSR incidence between the two; 
however, they did not perform a risk factor analysis. Sub-
jects in the study by Shao et al. [11] were ethnically closer 
to the present study subjects, and their sex and age were 
not predictive of HSRs. Moreover, in a previous Japanese 
study, Shibata et al. [9] investigated HSR occurrence in 125 
Japanese patients with colorectal cancer who were treated 
with FOLFOX4, FOLFOX6 or mFOLFOX6 therapy dur-
ing 2005–2006. These authors also reported no differences 
Fig. 2  Incidence of hypersensitivity reaction in mFOLFOX6 and 
XELOX therapy groups. Each data was expressed hypersensitivity 
reaction ratio. White bar was expressed mFOLFOX6 therapy group. 
Right hatched bar was expressed XELOX therapy group. P values 
calculated on Chi-squared test
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in sex or age between patients who experienced HSRs and 
those who did not. In contrast, in 108 Japanese colorectal 
cancer patients who were treated with FOLFOX4 and/or 
mFOLFOX6 therapy during 2005–2009, Seki et  al. [13] 
reported higher proportions of women and past allergic his-
tory among those with grade-1/2 HSRs than among those 
who did not suffer grade-1/2 HSR. However, our multivari-
ate analyses may more accurately reflect the effects of colo-
rectal cancer treatments on HSRs in the therapies that cur-
rently used frequently.
Although we compared mFOLFOX6 and XELOX thera-
pies in colorectal cancer patients, differences in treatment 
methods were not related to potential risk factors for HSRs. 
Therefore, differences in treatment methods were not explan-
atory of HSR. Moreover, age, metastasis, co-infusion of Dex 
with L-OHP and albumin and AST levels, which were sig-
nificant or near-significant factors in group comparisons of 
patient backgrounds, were not identified as significant risk 
factors. Therefore, differences in patient backgrounds were 
unlikely to affect HSR comparisons between the two groups. 
Furthermore, our multivariate analyses identified body sur-
face area ≥1.57  m2 as the only significant risk factor, with 
an odds ratio of 2.18. This body surface area was chosen as 
the threshold because there were no extreme outliers among 
these values and the median was considered to be an appro-
priate statistic. In addition, cumulative L-OHP dosages were 
excluded from risk factor analyses as both relative (mg/m2) 
and absolute (mg) values, which indicates that differences 
in L-OHP dosages relative to body surface area are highly 
unlikely to affect HSR incidence.
When comparing subjects with HSR, the median timing 
of HSR onset was 10.0 cycles in the mFOLFOX group and 
5.5 cycles in the XELOX group, which implies a signifi-
cant difference. Alternatively, further analyses showed that 
HSRs occurred before cycle 10 in 85.0% of patients who 
had HSRs during XELOX therapy, but only in 52.7% of 
FOLFOX-treated patients after cycle 10. Accordingly, in 
Japanese FOLFOX-treated patients, HSRs occurred at 9 
(4–16) cycles [7] and 9 (2–15) cycles [9], grade-1/2 HSRs 
occurred at 8.4 ± 4.4 cycles and grade-3/4 HSRs occurred 
at 9.3 ± 3.9  cycles [13]. In addition, using data from 156 
and 17 patients who experienced HSRs during FOLFOX 
and XELOX therapies, respectively, Lee et al. [21] reported 
that HSRs occurred at earlier cycles in the latter group of 
patients (6.6 ± 0.3 versus 3.1 ± 0.6 cycles). Although HSRs 
occurred earlier in their FOLFOX therapy group as com-
pared to that in our study, the observed earlier occurrence 
of HSRs in the XELOX therapy group is consistent with 
our results. In addition, no correlation between cumula-
tive dosage (mg/m2 or mg) and HSR incidence was iden-
tified in the present study, which suggests that the present 
differences in the cycle of HSR outbreak between the two 
groups are caused by the difference of L-OHP dosages per 
one cycle between the two groups. However, the high inci-
dence of HSRs during the first cycle of XELOX therapy 
warrants further investigation. In particular, HSRs to indi-
vidual platinum-based compounds occur at different times 
and via different mechanisms [4], but reportedly involve 
formation of platinum-sensitive IgE antibodies as a com-
mon pathogenic mechanism [22–24]. In addition, dem-
onstrated mechanisms underlying type I allergies to car-
boplatin are numerous [25], and markedly increased IgE 
levels were shown in a case report of patients with HSRs 
to L-OHP [26]. L-OHP has also been shown to act as a 
superantigen that induces IgE production in mononuclear 
cells [27]. Accordingly, HSRs to L-OHP is regarded as an 
acute reaction that occurs after repeat administration [18], 
typically after six cycles [4, 23], rather than at treatment 
initiation. However, the present data warrant attention to 
the cumulative L-OHP dosage and indicate that HSRs can 
occur during the first cycle of regimens with high L-OHP 
dosages, such as that in XELOX therapy.
On further analyses, high rates of grade-2 or higher 
grade HSRs were observed when Dex was not co-infused 
with L-OHP and when cumulative L-OHP dosages were 
≥600  mg/m2. Because L-OHP causes vascular pain due 
to its acidic pH, Yoshida et al. [28] added Dex to L-OHP 
infusions for raising the pH during XELOX therapy, which 
reduced vascular pain because L-OHP causes vascular pain 
due to its acidic pH. Hence, the co-infusion method is now 
widely used and Yoshida et  al. [19] showed significant 
decreases in HSR incidence following two co-injections of 
a total of 13.2 mg Dex, before and after L-OHP adminis-
tration during XELOX therapy. These authors described 
the possibility that a change in pH caused by co-infusion 
of Dex could influence histamine release as an inhibitory 
mechanism. Although the total dosage in the present study 
(6.6 mg) was half of their dosages, the incidence of grade-2 
and higher grade HSRs was lower after co-infusion of 
1.65 mg of Dex than that when Dex was not co-infused. As 
the conditions for Dex used in our regimen differed greatly 
from those in Yoshida et al.’s regimen, we were unable to 
reach a conclusion on the actual inhibitory mechanism. The 
incidence of HSRs at grade-2 and higher was completely 
inhibited in Yoshida et  al.’s regimen, but this was not the 
case for the regimen used in the present study. Identifica-
tion of this inhibitory mechanism by future studies would 
be beneficial for the prevention of HSRs. Finally, Kidera 
et  al. [12] compared HSR incidence between FOLFOX6-
treated patients who received 6.6 mg of Dex in all courses 
and those who received Dex for first five courses followed 
by oral treatment with 50  mg diphenhydramine, 16.5  mg 
Dex and 20 mg famotidine from the sixth course. The HSR 
rate was lower in the latter group (20 versus 7%). This 
effect could not be investigated in the present study because 
no subjects were administered H1 or H2 blockers.
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The present study was limited as a retrospective survey 
of medical records. Data related to HSRs were collected 
from descriptions in the medical records. The study only 
included colon and rectal cancer; this was to restrict the 
range of diagnoses and treatments across departments and 
thus to minimize any bias due to differences between staff 
involved in the treatment. Moreover, although 240 patients 
were included in analyses, HSRs occurred in only 16.3% 
of subjects, thus limiting subgroup analyses of those who 
experienced HSRs. However, in the current condition of 
constantly changing treatment methods, larger sample sizes 
are unlikely and warrant multicentre studies to confirm the 
present conclusions. However, even this will have limita-
tions; ideally, a prospective multicentre study should be 
conducted within a defined period of time.
Our findings indicate that XELOX therapy with high 
L-OHP dosages should be administered with attention to 
cumulative L-OHP dosages and possible occurrence of 
HSRs in the first cycle. The present data also suggests that 
grade-2 and higher grade HSRs may be reduced by co-infu-
sion of Dex with L-OHP. Finally, rates of ≥grade-2 HSRs 
are increased when cumulative L-OHP dosages exceed 
600 mg/m2.
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